Center of Experimental Therapeutics, Ludwig Center for Cancer Research, Department of Oncology, University of Lausanne, Lausanne 1011, Switzerland.
Vaccine Development Laboratory, Ludwig Center for Cancer Research, University of Lausanne, Lausanne 1011, Switzerland.
Curr Opin Biotechnol. 2020 Oct;65:190-196. doi: 10.1016/j.copbio.2020.03.003. Epub 2020 Apr 22.
New treatments are urgently needed in patients with ovarian cancer (OC), as diagnosis is delayed in many instances, resulting in 85% recurrence of the disease following surgery and standard chemotherapy. OC is considered to be an immunological type of cancer, despite its limited response to current immunotherapy options, including vaccination. Thus, additional interventions may improve their efficacy. Dendritic cells (DCs) are the most widely used cellular vaccination therapy in patients with OC due to their crucial role in the initiation and development of immune response. There are viable options for DC-vaccination with a favorable toxicity profile, but specific alternatives should consider the limited therapeutic effectiveness of DC-vaccination in OC treatment. In this respect, B-cells and macrophages provide additional possibilities that may be explored for immunotherapy. Here we consider the current state-of-the-art of immunotherapy strategies for OC treatment and evaluate their potential for future improvements.
在卵巢癌（OC）患者中迫切需要新的治疗方法，因为在许多情况下诊断被延迟，导致手术后和标准化疗后疾病复发率达到 85%。OC 被认为是一种免疫类型的癌症，尽管其对当前免疫治疗选择的反应有限，包括疫苗接种。因此，额外的干预措施可能会提高它们的疗效。树突状细胞（DCs）是 OC 患者中最广泛使用的细胞疫苗治疗方法，因为它们在免疫反应的启动和发展中起着至关重要的作用。有可行的 DC 疫苗接种方案选择，且具有良好的毒性特征，但具体的替代方案应考虑到 DC 疫苗接种在 OC 治疗中的有限治疗效果。在这方面，B 细胞和巨噬细胞提供了可能被探索用于免疫治疗的其他可能性。在这里，我们考虑 OC 治疗的免疫治疗策略的最新进展，并评估它们未来改进的潜力。
